Cancer Research · 2007 · 830 citations · 17 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyOncogenesCancer ProgressionColorectal CancerMalignant NeoplasmsOncogenic Signaling PathwaysRas Family OncogenesSignal Transduction In CancerAberrant Ras ActivationOncogenic Ras SignalingRaf SignalingRas Pathway ActivationRas SignalingRas Signaling ActivationRas Signaling Pathway
Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly(12)Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/RAF/MAPK signaling pathways in CRC patients.
17
Primer3 on the WWW for General Users and for Biologist Programmers
Steve Rozen, Helen Skaletsky · Humana Press eBooks · 2003 · 15.1K citations
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15